| Literature DB >> 33269758 |
Riccardo Manca1, Micaela Mitolo2, Iain D Wilkinson3, David Paling4, Basil Sharrack5, Annalena Venneri1.
Abstract
Cognitive impairments are commonly observed in patients with multiple sclerosis and are associated with lower levels of quality of life. No consensus has been reached on how to tackle effectively cognitive decline in this clinical population non-pharmacologically. This exploratory case-control study aims to investigate the effectiveness of a hypothesis-based cognitive training designed to target multiple domains by promoting the synchronous co-activation of different brain areas and thereby improve cognition and induce changes in functional connectivity in patients with relapsing-remitting multiple sclerosis. Forty-five patients (36 females and 9 males, mean age 44.62 ± 8.80 years) with clinically stable relapsing-remitting multiple sclerosis were assigned to either a standard cognitive training or to control groups (sham training and non-active control). The standard training included twenty sessions of computerized exercises involving various cognitive functions supported by distinct brain networks. The sham training was a modified version of the standard training that comprised the same exercises and number of sessions but with increased processing speed load. The non-active control group received no cognitive training. All patients underwent comprehensive neuropsychological and magnetic resonance imaging assessments at baseline and after 5 weeks. Cognitive and resting-state magnetic resonance imaging data were analyzed using repeated measures models. At reassessment, the standard training group showed significant cognitive improvements compared to both control groups in memory tasks not specifically targeted by the training: the Buschke Selective Reminding Test and the Semantic Fluency test. The standard training group showed reductions in functional connectivity of the salience network, in the anterior cingulate cortex, associated with improvements on the Buschke Selective Reminding Test. No changes were observed in the sham training group. These findings suggest that multi-domain training that stimulates multiple brain areas synchronously may improve cognition in people with relapsing-remitting multiple sclerosis if sufficient time to process training material is allowed. The associated reduction in functional connectivity of the salience network suggests that training-induced neuroplastic functional reorganization may be the mechanism supporting performance gains. This study was approved by the Regional Ethics Committee of Yorkshire and Humber (approval No. 12/YH/0474) on November 20, 2013.Entities:
Keywords: cognitive training; magnetic resonance imaging; multiple sclerosis; neuroplasticity; neuropsychology; rehabilitation; salience network
Year: 2021 PMID: 33269758 PMCID: PMC8224115 DOI: 10.4103/1673-5374.300450
Source DB: PubMed Journal: Neural Regen Res ISSN: 1673-5374 Impact factor: 5.135
STROBE Statement—Checklist of items that should be included in reports of case-control studies
| Item No | Recommendation | Page No | |
|---|---|---|---|
| 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 2 | |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2-3 | ||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 4-5 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 5 |
| Study design | 4 | Present key elements of study design early in the paper | 6-7 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 6-7, 11 |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls | 6-7 |
| (b) For matched studies, give matching criteria and the number of controls per case | 7 | ||
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 6, 11-12 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 11-12 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 6 |
| Study size | 10 | Explain how the study size was arrived at | 7 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 14-15 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 14 |
| (b) Describe any methods used to examine subgroups and interactions | 14 | ||
| (c) Explain how missing data were addressed | n.a. (no missing data) | ||
| (d) If applicable, explain how matching of cases and controls was addressed | 7 | ||
| (e) Describe any sensitivity analyses | n.a. | ||
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 7 |
| (b) Give reasons for non-participation at each stage | 6-7 | ||
| (c) Consider use of a flow diagram | Not applicable | ||
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 15, 31 |
| (b) Indicate number of participants with missing data for each variable of interest | Not applicable (no missing data) | ||
| Outcome data | 15* | Report numbers in each exposure category, or summary measures of exposure | 15, 35 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 15-17 |
| (b) Report category boundaries when continuous variables were categorized | Not applicable | ||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Not applicable | ||
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | 16-17, 34, 41 |
| Key results | 18 | Summarise key results with reference to study objectives | 18 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 21 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 19-20 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 21 |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 22 (no funding) |
*Give information separately for cases and controls.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine athttp://www.annals.org/, and Epidemiology athttp://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.
Acquisition parameters for the sequences included in the MRI protocol
| MRI sequence | Acquisition parameters |
|---|---|
| Sagittal 3-dimensional (3D) T1-weighted magnetization prepared rapid acquisition gradient-echo | Repetition time = 8.1 ms, echo time = 3.7 ms, matrix size = 240 × 222, field of view = 240 × 240 mm2 |
| Sagittal 3D T2-weighted fluid attenuated inversion recovery | Repetition time = 4800 ms, echo time = 289 ms, inversion time = 1000 ms, matrix size = 224 × 224, field of view = 250 × 250 mm2 |
| Axial 2D T2*-weighted, single-shot, echo planar imaging | Repetition time = 2600 ms, echo time = 35 ms, time points = 200, matrix size = 96 × 94, field of view = 230 × 230 mm2. Prior to the acquisition of this dataset, patients were instructed to close their eyes and rest without falling asleep. |
2D: 2-Dimensional; 3D: 3-dimensional; MRI: magnetic resonance imaging.
Clinical and demographic characteristics of the included patients
| Characteristic | Standard training | Sham training | Non-active control | ||
|---|---|---|---|---|---|
| Age (yr) | 45.40±10.55 | 45.73±8.61 | 42.73±7.27 | 0.51 | 0.604 |
| Age at onset (yr) | 36.80±9.92 | 37.13±8.40 | 32.73±6.86 | 1.25 | 0.297 |
| Education (yr) | 14.00±5.00 | 17.00±3.00 | 12.00±2.00 | 10.68† | 0.005 |
| Sex (F/M) | 13/2 | 10/5 | 13/2 | 2.50‡ | 0.287 |
| Disease duration (yr)* | 8.00 (7.00) | 6.00 (7.00) | 8.00 (13.00) | 0.31† | 0.856 |
| Relapses ( | 0.00 (1.00) | 0.00 (4.00) | 0.00 (2.00) | 3.09† | 0.213 |
| EDSS* | 3.50 (2.50) | 3.00 (3.00) | 4.00 (2.50) | 5.22† | 0.074 |
| GMV (mL) | 659.19±84.94 | 607.21±60.54 | 624.71±94.44 | 1.59 | 0.216 |
| WMV (mL) | 404.24±150.18 | 418.88±62.73 | 438.43±152.47 | 0.27 | 0.768 |
| TLV (mL)* | 3.26 (13.66) | 7.27 (12.55) | 5.91 (6.33) | 0.36† | 0.837 |
Values are means ± standard deviations. * Median and interquartile range; † Kruskal-Wallis test; ‡ Pearson chi-square test. n = 15 in each group. EDSS: Expanded Disability Status Scale; F: female; GMV: grey matter volume; M: male; TLV: total lesion volume; WMV: white matter volume.
Cognitive and self-reported characteristics of the sample and changes resulting from the three group-by-time repeated measures models
| Characteristic | Standard training | Sham training | Non-active control | Standard | Sham | Standard | ||||||
| Baseline | Post-training | Baseline | Post-training | Baseline | Post-training | |||||||
| PASAT 3”† | 35.93±17.79 | 41.87±16.35 | 36.87±19.90 | 39.80±16.33 | 39.53±14.41 | 43.07±13.90 | 0.30 | 0.587 | 0.92 | 0.347 | 2.87 | 0.102 |
| PASAT 2”† | 21.40±14.98 | 26.93±16.00 | 23.73±12.90 | 26.40±14.96 | 23.40±15.51 | 28.33±15.83 | 0.35 | 0.558 | 2.43 | 0.13 | 2.36 | 0.136 |
| DS -F† | 6.00±0.84 | 6.60±0.99 | 6.47±1.68 | 6.53±1.19 | 6.33±0.98 | 6.07±0.70 | 7.61 | 0.01 | 0.01 | 0.914 | 1.98 | 0.17 |
| DS -B† | 4.53±1.06 | 4.93±1.49 | 4.93±1.53 | 5.27±1.33 | 4.73±1.10 | 4.60±0.91 | 6.35 | 0.018 | 0.28 | 0.599 | 1.49 | 0.233 |
| LMT -IR† | 13.40±3.52 | 14.27±3.61 | 13.93±3.90 | 13.73±4.46 | 12.73±3.26 | 11.40±3.68 | 3.13 | 0.088 | 0.81 | 0.377 | 1.34 | 0.256 |
| LMT -DR† | 14.87±3.89 | 17.73±3.08 | 17.13±3.54 | 16.33±4.27 | 15.00±2.90 | 14.20±5.28 | 9.40 | 0.005 | 0.01 | 0.918 | 4.78 | 0.038 |
| BSRT -total† | 90.33±17.43 | 115.80±12.76 | 100.93±13.30 | 110.60±15.44 | 102.33±15.87 | 107.73±15.37 | 2.34 | 0.138 | ||||
| BSRT -DR† | 8.13±2.53 | 8.93±2.37 | 6.80±2.76 | 8.73±2.55 | 7.47±2.56 | 8.13±2.26 | 8.88 | 0.006 | 0.23 | 0.637 | 3.77 | 0.063 |
| PF† | 28.40±9.17 | 38.80±10.53 | 38.93±9.58 | 43.73±12.03 | 32.07±9.14 | 36.87±10.49 | 9.42 | 0.005 | 0.54 | 0.469 | 2.9 | 0.1 |
| SF† | 43.73±9.47 | 55.93±13.91 | 52.87±9.22 | 55.73±8.78 | 43.47±9.65 | 44.67±8.68 | 0.05 | 0.82 | ||||
| CT -span† | 4.87±1.19 | 5.47±1.24 | 4.73±1.22 | 5.00±1.36 | 4.93±1.16 | 5.40±0.91 | 0.27 | 0.608 | 0.22 | 0.642 | 3.94 | 0.057 |
| CT -SU† | 25.00±3.82 | 27.04±1.94 | 25.64±3.46 | 25.76±3.66 | 26.11±2.68 | 27.50±1.42 | 0.09 | 0.769 | 1.64 | 0.211 | 1.76 | 0.196 |
| RF -copy† | 34.80±1.37 | 35.00±1.00 | 33.47±2.53 | 34.20±2.31 | 34.80±1.37 | 34.93±1.03 | 0.05 | 0.824 | 0.29 | 0.594 | 0.01 | 0.93 |
| RF -DR† | 14.53±4.26 | 22.47±4.94 | 18.27±6.38 | 18.80±6.90 | 18.16±3.77 | 22.20±5.17 | 6.69 | 0.015 | 1.64 | 0.212 | < 0.01 | 0.988 |
| DCT† | 50.87±7.38 | 55.07±5.24 | 52.00±6.00 | 54.47±5.89 | 54.27±4.83 | 54.47±5.36 | 3.00 | 0.095 | 2.4 | 0.133 | 0.27 | 0.605 |
| TMT-A (s) | 44.33±14.45 | 35.67±14.36 | 36.00±9.88 | 33.67±9.55 | 36.47±16.91 | 34.00±13.89 | 3.55 | 0.071 | 1.31 | 0.262 | 2.30 | 0.141 |
| SS (s) | 17.83±3.87 | 15.50±2.72 | 17.53±2.65 | 16.63±3.12 | 16.33±3.07 | 17.13±3.80 | 6.3 | 0.018 | 2.55 | 0.122 | 0.65 | 0.428 |
| DSCT† | 62.20±16.56 | 69.07±16.92 | 62.60±13.24 | 67.00±15.29 | 64.20±16.87 | 70.87±21.75 | 0.03 | 0.86 | 0.15 | 0.704 | 0.60 | 0.446 |
| SI (s) | 16.27±8.63 | 12.10±5.46 | 16.10±5.99 | 14.97±5.47 | 15.40±7.62 | 13.87±4.68 | 3.90 | 0.059 | 0.1 | 0.758 | 0.79 | 0.381 |
| TMT-B-A (s) | 43.87±24.03 | 35.53±23.48 | 45.73±27.61 | 39.87±19.82 | 36.53±21.07 | 29.60±12.45 | 0.28 | 0.602 | 0.02 | 0.894 | 0.17 | 0.686 |
| MFIS‡ | 44.00±16.67 | 32.40±15.98 | 53.07±14.23 | 45.13±17.92 | 48.27±17.13 | 49.53±17.91 | 7.12 | 0.013 | 1.56 | 0.222 | 1.85 | 0.185 |
| PHQ-9‡ | 8.93±5.65 | 6.53±3.96 | 10.87±5.79 | 8.60±5.34 | 8.40±3.60 | 8.73±4.03 | 4.42 | 0.045 | 3.79 | 0.062 | < 0.01 | 0.987 |
| GAD-7‡ | 6.87±6.08 | 4.33±3.31 | 6.13±4.53 | 5.87±5.07 | 7.20±5.06 | 5.27±3.86 | 0.03 | 0.86 | 0.02 | 0.894 | 0.21 | 0.647 |
| MSQoL-54 -P‡ | 51.68±20.25 | 61.80±21.21 | 44.81±16.63 | 44.45±17.81 | 52.02±19.79 | 50.38±22.08 | 10.66 | 0.003 | 0.17 | 0.679 | 4.74 | 0.038 |
| MSQoL-54 -M‡ | 58.64±17.52 | 66.58±19.87 | 53.38±18.83 | 56.03±24.42 | 64.53±19.79 | 59.30±19.28 | 4.97 | 0.034 | 2.04 | 0.164 | 0.01 | 0.914 |
Values are means ± standard deviations. n = 15 in each group. * (in bold) Tests that survived Bonferroni correction: P < 0.002; † Total number of correct items; ‡ Total score n a Likert-like scale. BSRT: Buschke Selective Reminding Test; CT: Corsi Test; DCT: Digit Cancellation Test (total number of correct items detected on the three matrices in 45 seconds); DR: Delayed recall; DS: Digit Span-B/F (B: backward, F: forward); DSCT: Digit Symbol Coding Test (total number of correct items reported in 120 seconds); GAD-7: 7-item Generalized Anxiety Disorder; IR: Immediate recall; LMT: Logical Memory Test; MFIS: Modified Fatigue Impact Scale; MSQoL-54-M/P: 54-item Multiple Sclerosis Quality of Life (M: mental, P: physical); PASAT: Paced Auditory Serial Addition Test; PF: Phonemic Fluency; PHQ-9: 9-item Patient Health Questionnaire; PS: Processing speed; RF: Rey Figure; SF: Semantic Fluency; SI: Stroop inhibition (difference between completion time on colour-word inhibition trial and average completion time on word reading and colour naming trials); SS: Stroop speed (average of completion time for word reading and colour naming trials); SU: supraspan; TMT-A/B-A: Trail Making Test (A: part A, A–B: part B–part A difference).
Results of stepwise regression: association between cognitive improvements and changes in fatigue in the standard training group
| Variable | Regression coefficient | |
|---|---|---|
| MFIS change | –0.256 | 0.321 |
| MFIS change | –0.302 | 0.299 |
| Education | –0.531 | 0.679 |
| MFIS change | 0.044 | 0.811 |
| MFIS change | 0.093 | 0.647 |
| Education | 0.573 | 0.532 |
BSRT: Buschke Selective Reminding Test; MFIS: Modified Fatigue Impact Scale.
Results of Mann-Whitney U test: differences in accuracy of performance between the standard and sham training groups in the first and last training sessions
| Variable | Standard training | Sham training | ||
| Change calculation | 0.83 (1.00) | 0.33 (0.67) | 31.5 | 0.001* |
| Lexical odd one out | 0.88 (0.50) | 0.38 (1.00) | 29.0 | 0.001* |
| Semantic odd one out | 0.90 (0.40) | 0.70 (0.70) | 29.0 | 0.001* |
| Sematic inhibition | 0.67 (0.67) | 0.67 (0.67) | 89.5 | 0.505 |
| Verbal sequence completion | 0.90 (0.40) | 0.70 (0.80) | 38.5 | 0.003* |
| Visual sequence completion | 0.86 (0.29) | 0.57 (0.43) | 29.5 | 0.001* |
| Sentence completion | 1.00 (0.20) | 0.70 (0.70) | 24.5 | < 0.001* |
| Scene completion | 0.88 (0.50) | 0.75 (0.88) | 31.5 | 0.001* |
| Change calculation | 0.50 (0.66) | 0.42 (0.66) | 83.0 | 0.354 |
| Lexical odd one out | 1.00 (0.62) | 0.50 (0.75) | 30.5 | 0.001* |
| Semantic odd one out | 1.00 (0.50) | 0.50 (0.75) | 26.0 | 0.001* |
| Sematic inhibition | 0.50 (1.00) | 0.00 (1.00) | 52.0 | 0.020* |
| Verbal sequence completion | 1.00 (0.50) | 0.75 (1.00) | 56.0 | 0.033* |
| Visual sequence completion | 0.75 (0.50) | 0.50 (1.00) | 48.5 | 0.012* |
| Sentence completion | 0.75 (0.50) | 0.50 (1.00) | 45.0 | 0.008* |
| Scene completion | 1.00 (1.00) | 0.50 (1.00) | 32.0 | 0.001* |
Values are medians and interquartile ranges. *P < 0.05
Significant changes in resting-state functional connectivity within the salience network resulting from the repeated measures models (PFWE < 0.05)
| FC changes | Cluster extent | Side | Brain region (Brodmann Area) | MNI coordinates (mm) | |||
| Decrease | 110 | R | Anterior cingulate (24) | 4.9 | 20 | –6 | 42 |
| R | Anterior cingulate (24) | 4.81 | 12 | –2 | 40 | ||
| R | Anterior cingulate (32) | 4.03 | 18 | 6 | 42 | ||
| Decrease | 119 | L | Putamen | 5.3 | –28 | –22 | –2 |
| L | Thalamus | 3.81 | –16 | –16 | –2 | ||
| Increase | 160 | R | Fusiform gyrus (19) | 4.79 | 36 | –70 | –18 |
| R | Fusiform gyrus (37) | 4.37 | 34 | –58 | –24 | ||
| R | Middle occipital gyrus (18) | 4.06 | 30 | –82 | –12 | ||
FC: Functional connectivity; FEW: Family Wise Error; L: left; MNI: Montreal Neurological Institute and Hospital; R: right.